Combining a single priming dose of the anti–CTLA-4 agent tremelimumab and durvalumab significantly improved overall survival compared with durvalumab or sorafenib alone in the treatment of patients with unresectable hepatocellular carcinoma, according to new research.
Findings from the phase 3, randomized, open-label HIMALAYA trial presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (abstract 379) showed the combination was associated with a 22%